After a median follow-up of @ months , disease-free survival at @ years was @ % in the exemestane-ovarian suppression group and @ % in the tamoxifen-ovarian suppression group ( hazard ratio for disease recurrence , second invasive cancer , or death , @ ; @ % confidence interval -LSB- CI -RSB- , @ to @ ; P < @ ) .